Zoetis Inc.

Zoetis Inc. is a U.S.-based animal health company focused on medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health products. Its portfolio serves companion animals and livestock across more than 100 countries through direct sales and distributor channels.

71,8 %

28,2 %

+2,3 %

3.03

1.94

— Zoetis Inc.
%
Parasiticides30% Products used to prevent and treat parasites in companion animals and livestock.
Vaccines18% Immunization products for companion animal and livestock disease prevention.
Dermatology14% Therapies for skin and allergy conditions in companion animals.
Anti-infectives10% Antibiotic and infection-control products used mainly in livestock and veterinary care.
Pain and Sedation8% Products used for pain control, anesthesia, and procedural sedation in animals.
Diagnostics and Other Animal Health20% Diagnostics, biodevices, genetic tests, and other veterinary health services.

Zoetis sells primarily to veterinarians and livestock producers, with products often dispensed by prescription through...

  • Veterinariansprimary

    Buy prescription medicines, vaccines, diagnostics, and support services for companion animals and livestock.

  • Livestock producersprimary

    Buy products for cattle, swine, poultry, fish, and sheep to manage herd health and productivity.

  • Pet ownerssecondary

    Influence and sometimes purchase companion-animal products, especially where direct-to-consumer marketing matters.

  • Distributors and buying groupssecondary

    Purchase and resell products or negotiate on behalf of veterinary practices in non-direct markets.

Zoetis manages its business through two operating segments: the United States and International...

  • •Two operating segments: United States and International
  • •Direct commercial presence in about 45 countries
  • •Products sold in over 100 countries worldwide
  • •Emerging markets include Brazil, Chile, China, and Mexico
  • •International results are exposed to foreign exchange movements

Zoetis focuses on broadening its animal health portfolio across companion animals and livestock while maintaining...

01
Product innovation and lifecycle expansionmedium-term

New and improved products help address unmet animal-health needs and sustain relevance across species.

02
Direct customer engagementshort-term

Sales representatives and veterinary specialists help influence prescribing and build loyalty.

03
Geographic expansion and local market coveragemedium-term

Local presence improves access to veterinarians and producers and supports emerging-market growth.

04
Selective acquisitions and capability buildingmedium-term

Acquisitions can add products, diagnostics, manufacturing capacity, and research capabilities.

Zoetis faces customer concentration and channel-consolidation pressure, especially as veterinarians, livestock...

high

Customer and distributor consolidation

Larger veterinary groups, buying cooperatives, and distributors can demand lower prices.

Scope
Veterinarians, livestock producers, and distributors
Materiality
high
high

Tariffs and trade restrictions

Higher duties can increase raw material, component, and finished-goods costs and disrupt supply chains.

Scope
Global sourcing and cross-border sales
Materiality
high
high

Cybersecurity and IT disruption

Operational dependence on systems and remote work increases exposure to attacks and outages.

Scope
Global operations and customer-facing systems
Materiality
high
medium

Foreign exchange volatility

International revenue and earnings are translated from multiple currencies into U.S. dollars.

Scope
Brazilian real, euro, Mexican peso, Argentinian peso, Turkish lira
Materiality
high
medium

Generic competition and channel change

Generic products or shifts toward retail/e-commerce can reduce share and pricing power.

Scope
Companion animal and livestock product lines
Materiality
medium
Revenue deductions and incentives
Can affect revenue timing and margin comparability across periods
Goodwill and intangible asset impairment
Could create non-cash charges if product or business values decline
Fair value in acquisitions
Affects purchase accounting, amortization, and future earnings
Contingencies and tax estimates
May create volatility in provisions and effective tax rate

Zomedica Corp.

ZOMDF · Pharmaceutical Preparations

NEOGEN CORP

NEOG · In Vitro & In Vivo Diagnostic Substances

Elanco Animal Health Inc

ELAN · Pharmaceutical Preparations

Zentalis Pharmaceuticals, Inc.

ZNTL · Pharmaceutical Preparations

Pelthos Therapeutics Inc.

PTHS · Biological Products, (No Diagnostic Substances)

PHIBRO ANIMAL HEALTH CORP

PAHC · Pharmaceutical Preparations

: 11/08/2026